H5N1 News and Research

Latest H5N1 News and Research

Tetragenetics reports results from G-SOME H5N1 vaccine preclinical study

Tetragenetics Inc., a biotechnology company focused on the development of recombinant vaccines, today reported preclinical study results showing that an investigational nanoparticle-based influenza vaccine protects against a highly pathogenic H5N1 avian influenza strain.

6 Jan 2012

WHO issues warning about risks of research on human engineered bird flu

"The World Health Organization issued a stern warning on Friday to scientists who have engineered a highly pathogenic form of the deadly H5N1 bird flu virus, saying their work carries significant risks and must be tightly controlled," Reuters reports.

4 Jan 2012

Bird flu updates

The latest bird flu virus that killed a 39-year-old bus driver in the southern Chinese city of Shenzhen over the weekend is not yet transmissible between humans, Chinese health authorities said. The man, who lived in Shenzhen just across the border from Hong Kong, died from multi-organ failure on Saturday, a week after being admitted to hospital with a fever brought on by the virus, state media reported.

3 Jan 2012

Chinese man dies of bird flu

A 39 year old Chinese bus driver tested positive for the H5N1 bird flu virus and died Saturday in a city bordering Hong Kong. According to health officials this is the country’s first reported case of the disease in humans in 18 months.

2 Jan 2012

CEL-SCI to expand Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation is in the process of expanding its Phase III clinical trial of the investigational therapy Multikine (Leukocyte Interleukin, Injection) to 4 additional European countries - Spain, Czech Republic, Slovakia and Croatia.

27 Dec 2011

CEL-SCI reports net loss of $26.8M for fiscal year ended September 30, 2011

CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2011.

26 Dec 2011

Federal officials seek to keep details on bird flu study secret

A federal board has asked two scientific journals to restrict access to details of a genetic study of the bird flu in which researchers altered the virus to be more easily transmittable between humans.

23 Dec 2011

Longer looks: Manufacturing killer flu; The ironies of the individual mandate; When the elderly refuse help

In experiments conducted at the University of Wisconsin in Madison and Erasmus University in Rotterdam, the Netherlands, researchers engineered a strain of H5N1. … The next logical step would be for the researchers to publish studies in major scientific journals, describing the newly created flu, including its genetic makeup.

23 Dec 2011

First Edition: December 22, 2011

Today's early morning highlights from the major news organizations, including articles on the Capitol Hill stalemate that threatens to cut Medicare payments to doctors and government efforts to keep details of a research experiment on bird flu secret.

22 Dec 2011

U.S. Science Advisory Board asks Science, Nature to omit data from bird flu studies amid security concerns

The U.S. National Science Advisory Board for Biosecurity on "Tuesday asked two scientific journals to leave out data from research studies on a lab-made version of bird flu that could spread more easily to humans, fearing it could be used as a potential weapon," Reuters reports.

22 Dec 2011

Virus with potential for bioterrorism created – Experts worried

Two major scientific journals are debating on whether to publish details of a man-made mutant flu virus that could kill billions, after a US government's science advisory committee advised them to withhold key details.

21 Dec 2011

NanoViricides submits pre-IND Meeting Request for FluCide to FDA

NanoViricides, Inc. announced today that it has submitted a pre-IND Meeting Request to the US FDA. The Company has requested an initial meeting with the US FDA to review the Company's proposed strategy and plan for conducting safety/toxicology studies and human clinical trials required for approval of its anti-influenza clinical drug candidate, FluCide™ (i.e. NV-INF-1).

5 Dec 2011

Inovio announces results from SynCon avian influenza vaccine Phase I study

Inovio Pharmaceuticals, Inc., which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that a single intradermal (ID) electroporation boost of its SynCon avian influenza vaccine generated HAI titers against six different, unmatched strains of H5N1 - a distinct new clinical achievement on the global research community's path to develop universal influenza vaccines.

18 Nov 2011

Sinovac third quarter sales increase 60.8% to $15.4 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited third quarter financial results for the period ended September 30, 2011.

14 Nov 2011

Encouraging results from SEEK's FLU-v Phase II study

SEEK, a leading UK privately-owned drug-discovery group, today announced encouraging results following the successful completion of its Universal Flu Vaccine Phase II challenge study.

7 Nov 2011

NanoViricides President completes stock sales program

NanoViricides, Inc. announced that its President, Dr. Anil Diwan, has completed the programmed sale of the NanoViricides stock that he had obtained as a founder.

18 Oct 2011

CEL-SCI closes previously announced registered direct offering

CEL-SCI Corporation announced today that it has closed its previously announced registered direct offering for the sale of (i) 13,333,334 shares of its common stock at a price per share of $0.30 and (ii) warrants to purchase up to 12,000,000 shares of CEL-SCI Corporation's common stock at a purchase price of $0.40. The warrants may be exercised at any time prior to October 6, 2014.

7 Oct 2011